证券代码：002950 证券简称：奥美医疗 编号：2020-005 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------|------------------------------|------------------------------------------------------| | | | | | 投 资 者 关 系 活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 （电话会议） | | | 参 与 单 位 名 称 | 详见附件《参会机构名单》 | | | 及人员姓名 | | | | 时间 | 2020 年 7 月 12 日 | | | 地点 | 电话会议 | | | 上 市 公 司 接 待 | | 董事长 崔金海；董事、董事会秘书 杜先举；证券事务代表 | | 人员姓名 | 郑晓程。 | | | 投 资 者 关 系 活 | 1 | 、请公司介绍上半年业绩，比如说口罩类业务的 ...

证券代码：002950 证券简称：奥美医疗 编号：2020-003 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------|------------------------------|------------------------------------------------------| | | | | | 投 资 者 关 系 活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 （电话会议） | | | 参 与 单 位 名 称 | 详见附件《参会机构名单》 | | | 及人员姓名 | | | | 时间 | 2020 年 3 月 26 日 | | | 地点 | 电话会议 | | | 上 市 公 司 接 待 | | 董事、副总裁兼董事会秘书 杜先举；证券事务代表 郑晓程 | | 人员姓名 | | | | 投 资 者 关 系 活 | 1. | 能否介绍下与国药器械签署合作的情况。 | | 动 ...

证券代码：002950 证券简称：奥美医疗 编号：2020-004 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------|-------------------------|----------------------------------------------------| | | | | | 投 资 者 关 系 活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | √ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （电话会议） | | | 参 与 单 位 名 称 | 奥美医疗 2019 | 年度业绩网上说明会暨重大投资项目说明会 | | 及人员姓名 | 参会投资者 | | | 时间 | 2020 年 5 月 13 | 日 | | 地点 | 约调研、同花顺路演平台 | | | 上 市 公 司 接 待 | | 董事长及总裁崔金海，董事、副总裁兼董事会秘书杜先 | | 人员姓名 | | 举，董事、董事、副总裁兼财务总监黄文剑，独立董事蔡 | ...

证券代码：002950 证券简称：奥美医疗 编号：2020-001 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 天风证券 郑薇；景顺长城 姜雪婷；高毅资产 冯鹏；宝盈基 | | 人员姓名 | | 金 李进；大成基金 魏庆国；普渡资产 黄锐平；中庚基金 余 | | | | 思慧；云溪基金 程婷婷；康泰资产 陈璟；鹏华基金 郎超； | | | 通晟资产 张烨。 | | | 时间 | 2020 年 1 月 10 | 日下午 | | 地点 | | 深圳市奥美迪贸易发展有限 ...

证券代码：002950 证券简称：奥美医疗 编号：2020-002 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------|-----------------------------|----------------------------------------------------| | | | | | 投 资 者 关 系 活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 （分析师电话会议） | | | 参 与 单 位 名 称 | 详见附件《参会机构名单》 | | | 及人员姓名 | | | | 时间 | 2020 年 2 月 9 日 | | | 地点 | 电话会议 | | | 上 市 公 司 接 待 | | 董事、董事会秘书 杜先举；证券事务代表 郑晓程 | | 人员姓名 | | | | 投 资 者 关 系 活 | 1. | 能否介绍下公司口罩的供应情况。 | | 动 主 要 内 容 ...

证券代码：002950 证券简称：奥美医疗 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------------|------------------------------------------------|------------------------------------------------------------------------------------|------------| | | | 编号： | 2021-001 | | 投 资 者关 系 活 | □ 特定对象调研 | □ 分析师会议 | | | 动类别 | □ 媒体采访 | √ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | | | | | □ 其他 （电话会议） | | | | 参 与 单位 名 称 及人员姓名 | 线上公众投资者 | | | | 时间 | 2021 年 5 月 11 日 | | | | 地点 | "奥美医疗投资者关系"微信小程序 | | | | 上 市 公司 接 待 | ...

证券代码：002950 证券简称：奥美医疗 奥美医疗用品股份有限公司投资者关系活动记录表 编号：2021-002 | --- | --- | --- | --- | |---------------|------------------------------------------------------|--------------------------------------------------|---------------| | | | | | | 投资者 关系活 | □ 特定对象调研 | □ 分析师会议 | | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | | | | | √ 其他 湖北上市公司 2021 | 年度投资者网上集体接待日活动 | | | 参与单 位名称 | 线上公众投资者 | | | | 及人员姓名 | | | | | 时间 | 2021 年 6 月 24 日 | | | | 地点 | 全景网投资者关系互动平台 | | | | 上市公 司接待 | 董事、副总裁兼董事会秘书 | 杜先举；证券事 ...

股票代码：002950 股票简称：奥美医疗 奥美医疗用品股份有限公司投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | |-----------------------|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-------| | | | | | | 投资者关系活动类 | □ 特定对象调研 □ | 分析师会议 | | | 别 | □ 媒体采访 | √业绩说明会 | | | | □ 新闻发布会 □ | 路演活动 | | | | □ 现场参观 | | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及人 | 线上参与公司奥美医疗 | 2021 年度网上业绩说明会的投 | | | 员姓名 | 资者 | | | | 时间 | 202 ...

Revenue and Profitability - The company's revenue for Q3 2022 was ¥932,733,147, representing a 12.29% increase year-over-year, and a total revenue of ¥3,067,161,380.95 for the year-to-date, which is a 31.79% increase compared to the same period last year[3] - The net profit attributable to shareholders for Q3 2022 was a loss of ¥93,224,648.75, a decrease of 202.04% year-over-year, while the year-to-date net profit was ¥196,873,537.48, down 40.18% compared to the previous year[3] - Total operating revenue for the current period reached ¥3,067,161,380.95, a significant increase from ¥2,327,252,559.38 in the previous period, representing a growth of approximately 31.7%[16] - Net profit for the current period was ¥196,749,394.55, down from ¥330,867,284.85 in the previous period, reflecting a decrease of approximately 40.5%[17] - The total comprehensive income for the current period was ¥289,534,919.49, slightly down from ¥323,648,414.38 in the previous period, a decrease of about 10.5%[17] Cash Flow and Financial Position - The cash flow from operating activities for the year-to-date was ¥900,860,648.94, showing a significant increase of 275.58% compared to the same period last year[3] - The net cash flow from operating activities improved to ¥900,860,648.94, compared to ¥239,857,506.40 in the previous period, indicating a growth of about 274.5%[19] - The company reported a net cash outflow from investing activities of ¥1,067,174,157.15, compared to a net outflow of ¥941,221,354.73 in the previous period, indicating an increase in cash outflow of about 13.4%[19] - Net cash flow from financing activities was -236,928,160.88 CNY in Q3 2022, compared to -313,448,681.28 CNY in Q3 2021, indicating an improvement year-over-year[20] - The company reported a net decrease in cash and cash equivalents of -382,609,401.33 CNY for Q3 2022, compared to -1,013,433,841.51 CNY in Q3 2021, showing a significant reduction in cash burn[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,542,843,747.46, reflecting a 10.75% increase from the end of the previous year[3] - Total assets as of September 30, 2022, amounted to CNY 5,542,843,747.46, an increase from CNY 5,004,829,011.10 at the beginning of the year[13] - Total liabilities reached CNY 2,634,249,126.42, compared to CNY 2,252,783,574.08 at the beginning of the year[14] - The company's total equity attributable to shareholders at the end of the reporting period was ¥2,907,662,991.66, a 5.62% increase from the end of the previous year[3] - The company's total equity as of September 30, 2022, was CNY 2,908,594,621.04, up from CNY 2,752,045,437.02[14] Shareholder Information - The number of common shareholders at the end of the reporting period was 47,822[10] - The top shareholder, Cui Jinhai, holds 23.02% of the shares, totaling 145,794,859 shares[10] Expenses and Financial Performance - The company's basic and diluted earnings per share for Q3 2022 were both -¥0.1472, a decrease of 202.04% year-over-year[3] - The company's research and development expenses decreased by 21.46% year-over-year to ¥45,635,755.64[8] - The financial expenses increased significantly by 1636.59% year-over-year to ¥199,980,941.51, primarily due to exchange losses from the depreciation of the RMB against the USD[8] - The company experienced a loss in investment income of ¥9,128,577.84, contrasting with a gain of ¥23,145,832.72 in the previous period[16] - Basic earnings per share decreased to ¥0.3109 from ¥0.5197, reflecting a decline of approximately 40%[17]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 2.13 billion, representing a 42.62% increase compared to CNY 1.50 billion in the same period last year [29]. - The net profit attributable to shareholders for the first half of 2022 was approximately CNY 290.10 million, a 22.01% increase from CNY 237.77 million in the previous year [29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately CNY 307.22 million, reflecting a significant increase of 55.47% compared to CNY 197.61 million in the same period last year [29]. - The net cash flow from operating activities reached approximately CNY 559.15 million, a remarkable increase of 698.05% from CNY 70.06 million in the previous year [29]. - The total assets at the end of the reporting period were approximately CNY 5.66 billion, up 13.07% from CNY 5.00 billion at the end of the previous year [29]. - The net assets attributable to shareholders at the end of the reporting period were approximately CNY 2.95 billion, an increase of 7.12% from CNY 2.75 billion at the end of the previous year [29]. - The company reported a basic earnings per share of CNY 0.4581, which is a 22.00% increase compared to CNY 0.3755 in the same period last year [29]. - The weighted average return on equity for the reporting period was 10.01%, an increase of 2.46% from 7.55% in the previous year [29]. Market Strategy and Expansion - The company plans to enhance its market presence in emerging markets such as the Middle East and Africa, as well as expand its domestic medical supplies market share [6]. - The company aims to strengthen its partnerships with key international medical device brands to secure stable revenue streams [6]. - The company is focused on the medical dressing market, which is expected to grow due to increasing demands for wound healing and comfort from patients [38]. - The company is positioned to capitalize on the growing demand for high-quality medical dressings in both domestic and international markets [43]. - The company aims to expand its product line by adding high-value consumables based on existing products like Vaseline gauze [46]. - The company has developed a series of new products tailored to different market needs, including sterile care packages for medical institutions and a range of personal protective products for the retail market [69]. Risk Management - The company has implemented strategies to mitigate risks associated with raw material price fluctuations, including centralized procurement and local sourcing to manage costs effectively [8]. - The company is exposed to foreign exchange risks due to its foreign currency-denominated sales, and it has adopted measures such as careful currency selection and the use of financial instruments to hedge against these risks [9]. - The company has established a professional derivatives trading team to manage risks related to raw material procurement and currency fluctuations [11]. - The company emphasizes the importance of maintaining a robust internal control system for its derivative transactions to mitigate trading risks [11]. - The company has implemented a comprehensive risk management system for foreign exchange derivative transactions, ensuring no speculative operations are conducted [110]. Product Development and Innovation - The company is committed to ongoing research and development of new products and technologies to enhance its competitive edge in the medical supplies market [6]. - The company has developed a comprehensive range of wound care solutions, including non-stick wound pads and various types of gauze [47]. - The surgical consumables segment includes innovative products like X-ray detectable gauze and non-woven surgical drapes [50]. - The company has invested in R&D and innovation, resulting in multiple software copyrights and patents, maintaining its competitive edge in the medical dressing sector [77]. - The company aims to continue focusing on market demand and core technologies to create tailored product solutions for different scenarios [70]. Corporate Governance and Financial Management - The company will not distribute cash dividends or issue bonus shares, indicating a focus on reinvestment [12]. - The company has implemented a comprehensive quality management system, adhering to international standards such as ISO13485 and FDA regulations, which has strengthened customer confidence [76]. - The company has no significant changes in asset measurement attributes during the reporting period [93]. - The company has not reported any significant litigation or arbitration matters during the reporting period [132]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period [137]. Social Responsibility and Community Engagement - In response to the COVID-19 pandemic, the company donated over 2 million RMB worth of medical supplies to various regions, including 500,000 RMB worth of supplies to Shenzhen [120]. - The company supplied over 40 million masks and 100,000 bottles of hand sanitizer to Shanghai during the peak of the outbreak from March to April 2022 [123]. - The company donated nearly 4.78 million surgical masks valued at approximately 2 million RMB to support high school students and staff during the 2022 examination period [124]. - The company provided 200,000 KN95 masks and medical protective masks valued at 450,000 RMB to the Hong Kong Federation of Trade Unions to assist in combating COVID-19 [121]. - The company arranged for 17.5 containers of supplies to support Shanghai's epidemic prevention efforts [123]. Financial Position and Assets - The company's total assets increased to CNY 4,235,642,730.72, compared to CNY 4,147,088,396.72 at the end of the first half of 2021 [181]. - The company's total liabilities increased to RMB 2,709,319,506.74 as of June 30, 2022, up from RMB 2,252,783,574.08, indicating a rise of approximately 20.2% [177]. - The company's equity attributable to shareholders rose to RMB 2,948,899,521.84 from RMB 2,752,953,286.33, marking an increase of about 7.1% [177]. - The company's inventory stood at RMB 853,700,859.44 as of June 30, 2022, slightly up from RMB 846,628,943.74 at the beginning of the year [175]. - The company's accounts receivable rose to RMB 502,029,260.61 from RMB 425,145,128.23, an increase of about 18.1% [175].